Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

Hong Kong biotech start-up works with university partners to conduct global clinical trials studying prevalent eye diseases.

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...

H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant volatility, with ...

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $85.7 million focused on developing therapies for ocular diseases, has announced ...

继在1月底公告全球首款眼科双抗Vabysmo在2024年大卖44亿美元，2月4日罗氏的Susvimo（100mg/mL雷珠单抗注射液）获得FDA的批准，用于治疗糖尿病性黄斑水肿（DME），眼科已经俨然成为了带动这家MNC业绩增长的“利剑”之一。